Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Transgenic animals may help resolve a sticky situation in cystic fibrosis
Jonathan H. Widdicombe
Jonathan H. Widdicombe
Published August 25, 2010
Citation Information: J Clin Invest. 2010;120(9):3093-3096. https://doi.org/10.1172/JCI44235.
View: Text | PDF
Commentary

Transgenic animals may help resolve a sticky situation in cystic fibrosis

  • Text
  • PDF
Abstract

Cystic fibrosis (CF) is caused by defects in the CFTR, a cAMP-activated Cl– channel of epithelia. The resulting reduction in epithelial fluid transport creates abnormally viscous secretions from airway mucous glands that may be a major factor in CF pathology. Mouse airways have few mucous glands, and the mouse model of CF exhibits no significant airway disease. Pigs and ferrets, however, have approximately the same number of airway mucous glands as humans. In this issue of the JCI, three independent research groups conclude that changes in airway mucous gland function in CFTR-deficient animals of these species resemble the changes seen in human CF. It is expected, therefore, that these animals will develop lung disease similar to human CF and prove to be valuable models on which to test potential therapies.

Authors

Jonathan H. Widdicombe

×

Figure 1

Means by which VIP (or other cAMP-elevating agents) stimulates Cl– secretion by airway gland serous cells.

Options: View larger image (or click on image) Download as PowerPoint
Means by which VIP (or other cAMP-elevating agents) stimulates Cl– secre...
(A) Low levels of VIP are insufficient to stimulate Cl– secretion but do elevate cAMP sufficiently to open CFTR. Low levels of acetylcholine (ACh) (also subthreshold for secretion) raise [Ca2+]i sufficiently to open basolateral K+ channels (GK). Together, the two agents induce Cl– secretion, as previously suggested by Choi et al. (10). (B) High levels of VIP elevate cAMP sufficiently to activate both Cl– and K+ channels, as previously suggested by Choi et al. (10). (C) cAMP elevates [Ca2+]i, which then activates basolateral K+ channels, as described by Lee and Foskett (9). (D) If the effects of cAMP on [Ca2+]i are somehow enhanced then VIP can induce Cl– secretion in CF cells by activating CaCC, as suggested by Lee and Foskett (9).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts